In the BioHarmony Drug Report Database

"Preview" Icon

Apalutamide

Erleada (apalutamide) is a small molecule pharmaceutical. Apalutamide was first approved as Erleada on 2018-02-14. It has been approved in Europe to treat prostatic neoplasms. The pharmaceutical is active against androgen receptor. Erleada’s patents are valid until 2038-04-30 (FDA).

 

Trade Name

 

Erleada
 

Common Name

 

apalutamide
 

ChEMBL ID

 

CHEMBL3183409
 

Indication

 

prostatic neoplasms
 

Drug Class

 

Non-steroid antiandrogens

Image (chem structure or protein)

Apalutamide structure rendering